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GENERAL CONSIDERATIONS
The most common congenital heart lesions that have been
associated with sudden death during sports participation are
hypertrophic cardiomyopathy, coronary artery anomalies,
Marfan syndrome, and aortic valve disease (1–3). Less
common lesions include complex defects, such as transpo-
sition and single ventricle, and those with associated pul-
monary vascular disease.
The recommendations presented are intended to provide
broad guidelines for patients with congenital heart defects
(4). When questions about the safety of sports participation
arise, there is no substitute for a comprehensive evaluation
by a knowledgeable and experienced physician. Exercise
testing can be useful, particularly if symptoms, the electro-
cardiogram (ECG), and blood pressure are monitored
during conditions that simulate the sport in question.
Arrhythmias discussed in this Task Force are usually iden-
tified by exercise testing or some form of long-term moni-
toring (including ambulatory Holter and event recording).
Serial evaluations may be required because of changing
hemodynamic status with time.
TYPES OF CONGENITAL DEFECTS
Atrial septal defect (ASD)— untreated. Most children
with ASD are asymptomatic, and closure is usually carried
out before they are active in competitive sports. An ECG
and echocardiogram are required for evaluation. Small atrial
defects are characterized by minimal or no right ventricular
volume overload, moderate or large defects have significant
volume overload but pulmonary hypertension is unusual.
Recommendations:
1. Athletes with small defects, normal right heart vol-
ume, and no pulmonary hypertension can participate
in all sports.
2. Athletes with a large ASD and normal pulmonary
artery pressure can participate in all competitive sports.
3. Athletes with an ASD and mild pulmonary hyperten-
sion can participate in low-intensity competitive
sports (class IA). Patients with associated pulmonary
vascular obstructive disease who have cyanosis and a
large right-to-left shunt cannot participate in com-
petitive sports.
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4. Athletes with ASD and symptomatic atrial or ven-
tricular tachyarrhythmia or moderate-to-severe mi-
tral regurgitation should follow the recommenda-
tions in Task Force 1: Preparticipation Screening
and Diagnosis of Cardiovascular Disease in Athletes,
and Task Force 6: Coronary Artery Disease,
respectively.
ASD— closed at operation or by interventional catheter-
ization. The ASDs usually are completely closed by oper-
ation or device insertion. When closure is performed in
childhood there is little or no residual right ventricular
enlargement. Supraventricular arrhythmias can occur after
closure and are more common when the defect is repaired
later in life (5–7). Evaluation should include an estimate of
cardiac performance, pulmonary vascular resistance and
right ventricular size, and a search for conduction or rhythm
disturbances. A chest radiograph, ECG, and echocardio-
gram usually are needed. Patients with preoperative pulmo-
nary hypertension, a right-to-left shunt, or both, before
operation require postoperative assessment of pulmonary
artery pressure with Doppler echocardiography or cardiac
catheterization.
Recommendations:
1. Three to six months after the operation or interven-
tion, patients can participate in all sports unless the
following are present: 1) evidence of pulmonary
hypertension; 2) symptomatic atrial or ventricular
tachyarrhythmias or second- or third-degree heart
block; and 3) evidence of myocardial dysfunction.
2. Patients with any of these abnormalities should have
an exercise evaluation and an individualized exercise
prescription with respect to competitive sports. For
related recommendations on competitive sports par-
ticipation, see the section entitled Elevated Pulmo-
nary Resistance and Ventricular Dysfunction After
Cardiac Surgery in this Task Force report, as well as
Task Force 7: Arrhythmias.
Ventricular septal defect (VSD)— untreated. The VSDs
are categorized as small, moderate, or large. If physical
examination and echocardiography indicate normal heart
size and normal pulmonary artery pressure in patients with
a suspected small VSD, further evaluation is not required.
A patient with a VSD that does not fit into the small
defect category may require further investigation. Cardiac
catheterization might be required.
A moderate-sized defect with low pulmonary vascular resis-
tance will have a pulmonary/systemic flow ratio of about 1.5 to
1.9. A large defect with low or mildly increased pulmonary
vascular resistance is defined as a pulmonary/systemic flow
ratio greater than or equal to 2 and pulmonary resistance less
than 3 U/m2. Large right-to-left shunts are discussed in the
section entitled Elevated Pulmonary Resistance.
Recommendations:
1. Athletes with a VSD and normal pulmonary artery
pressure can participate in all sports.
2. Athletes with a large VSD who do not have marked
elevation of pulmonary resistance are candidates for
repair, and full participation in all sports would
normally occur after a successful VSD closure.
VSD— closed at operation or by interventional catheter-
ization. Successful repair is characterized by the absence of
symptoms, absence of significant shunt, cardiomegaly, or
arrhythmias, and the presence of normal pulmonary artery
pressure. Minimal diagnostic evaluation after surgery before
participation in sports includes a chest radiograph, ECG,
and echocardiogram. Patients with residual left or right
ventricular enlargement, myocardial dysfunction, or pulmo-
nary hypertension may require an exercise test or cardiac
catheterization before a decision for participation in sports
can be made.
Recommendations:
1. At three to six months after repair, asymptomatic
athletes with no defect or only a small residual defect
can participate in all competitive sports if they have
no evidence of pulmonary artery hypertension, ven-
tricular or atrial tachyarrhythmia, or myocardial dys-
function.
2. Athletes with symptomatic atrial or ventricular
tachyarrhythmias or second- or third-degree atrio-
ventricular (AV) block should follow the recommen-
dations in Task Force 7: Arrhythmias. Athletes with
mild-to-moderate pulmonary hypertension or ven-
tricular dysfunction should follow the recommenda-
tions in the section entitled Elevated Pulmonary
Resistance or Ventricular Dysfunction After Cardiac
Surgery.
3. Athletes with persistent, severe pulmonary hyperten-
sion cannot participate in competitive sports (see
section entitled Elevated Pulmonary Resistance).
Patent ductus arteriosus (PDA)— untreated. The patient
with a small PDA has a characteristic murmur, absence of
symptoms, and normal left heart chamber dimensions.
Those with a larger patent ductus have cardiomegaly and
widened pulse pressure. There may be evidence of pulmo-
nary hypertension. Minimal diagnostic studies generally
include echocardiography.
Recommendations:
1. Athletes with a small PDA and normal left heart
chamber dimension can participate in all competitive
sports.
2. Athletes with a moderate or large PDA, causing left
ventricular (LV) enlargement, should undergo surgi-
cal or interventional catheterization closure before
unrestricted competition.
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3. For athletes with a moderate or large PDA, severe
pulmonary hypertension, and cyanosis, see the sec-
tion entitled Elevated Pulmonary Resistance.
PDA, closed at operation or by interventional catheter-
ization. A successful result is characterized by the absence
of symptoms, a normal cardiac examination, and normal
echo/Doppler study.
Recommendations:
1. Three months after PDA closure, patients with no
symptoms, with normal cardiac examination, and
with no evidence of pulmonary hypertension or LV
enlargement can participate in all competitive sports.
2. For athletes with residual pulmonary artery hyperten-
sion see the section entitled Elevated Pulmonary
Resistance.
Pulmonary valve stenosis (PS)— untreated. Mild stenosis
is characterized by a systolic ejection murmur, variable
ejection click, and a normal ECG. A Doppler peak in-
stantaneous gradient less than 40 mm Hg usually indicates
mild stenosis, 40 to 60 mm Hg moderate stenosis, and
greater than 60 mm Hg severe stenosis. Most patients with
a gradient 50 mm Hg or greater undergo balloon
valvuloplasty.
Recommendations:
1. Athletes with a peak systolic gradient less than 40
mm Hg and normal right ventricular function can
participate in all competitive sports if no symptoms
are present. Annual re-evaluation is recommended.
2. Athletes with a peak systolic gradient greater than 40
mm Hg can participate in low-intensity competitive
sports (classes IA and IB). Patients in this category
usually are referred for balloon valvuloplasty or op-
erative valvotomy before sports participation.
PS—treated by operation or balloon valvuloplasty. Ad-
equate relief of PS is characterized by the absence or
improvement in symptoms, an improved physical examina-
tion, and Doppler study showing mild or no residual
gradient and mild or no pulmonary valvular regurgitation.
Recommendations:
1. Athletes with no or only residual mild PS and normal
ventricular function without symptoms can partici-
pate in all competitive sports. Participation in sports
can begin two to four weeks after balloon valvulo-
plasty. After operation, an interval of approximately
three months is suggested before resuming sports
participation.
2. Athletes with a persistent peak systolic gradient greater
than 40 mm Hg should follow the same recommenda-
tions as those for patients before treatment.
3. Athletes with severe pulmonary incompetence charac-
terized by a marked right ventricular enlargement can
participate in class IA and IB competitive sports.
Aortic valve stenosis (AS)— untreated. This section dis-
cusses congenital valvular AS in young patients; AS in
adults is addressed in Task Force 3. Differentiation between
mild and either moderate or severe AS is accomplished by
physical examination, ECG, and Doppler echocardiogra-
phy. The distinction between moderate or severe stenosis is
more difficult and may require cardiac catheterization in rare
situations when clinical examination, ECG, echocardiogra-
phy, and/or other data are discrepant. Patients with a
history of fatigue, light-headedness, dizziness, syncope,
chest pain, or pallor on exercise deserve a full evaluation,
which may include cardiac catheterization and exercise
testing. Because AS may progress, periodic re-evaluation is
needed. Sudden death is more likely to occur in patients
with severe LV hypertrophy, exertional syncope, chest pain
or dyspnea and a LV strain pattern on the ECG. Between
approximately 20% and 80% of sudden deaths in patients
with severe AS have been found to occur on physical
exertion (2,8).
For the purpose of these recommendations, Table 1
summarizes the definitions of mild moderate and severe AS.
It should be emphasized that virtually all patients classified
as moderate or severe AS would be expected to have left
ventricular hypertrophy by echocardiography.
Recommendations:
1. Athletes with mild AS can participate in all compet-
itive sports if they have a normal ECG, normal
exercise tolerance, and no history of exercise-related
chest pain, syncope, or atrial or ventricular tachyar-
rhythmia associated with symptoms.
2. Athletes with moderate AS can participate in low
static/low-to-moderate dynamic, and moderate static/
low-to-moderate dynamic (classes IA, IB, and IIA)
competitive sports if the following conditions are met:
• Mild or no LV hypertrophy by echocardiography
and the absence of LV strain pattern on the ECG.
Table 1. Definitions of Mild, Moderate, and Severe Aortic Stenosis
Peak-to-Peak Systolic
Gradient (Catherization)
Mean Echo Doppler
Gradient (CW)
Peak Instantaneous Echo
Doppler Gradient (CW)*
Mild AS less than 30 mm Hg less than 25 mm Hg less than 40 mm Hg
Moderate AS 30 to 50 mm Hg 25 to 40 mm Hg 40 to 70 mm Hg
Severe AS greater than 50 mm Hg greater than 40 mm Hg greater than 70 mm Hg
*Gradients obtained from apical window usually most predictive of catheter gradient.
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• Normal exercise test without evidence of myocar-
dial ischemia or atrial or ventricular tachyarrhyth-
mia and with normal exercise duration and blood
pressure response. Those athletes with supraven-
tricular tachycardia or multiple or complex ven-
tricular tachyarrhythmias at rest or with exercise
can participate only in low-intensity competitive
sports, classes IA and IB.
• Absence of symptoms, as defined in the preceding
text.
3. Athletes with severe AS should not participate in
competitive sports.
The criteria in this section also apply to athletes with
discrete (membranous) subaortic stenosis and supravalvular
aortic stenosis.
Aortic stenosis—treated by operation or balloon valvu-
loplasty. After operation, a variable degree of residual
stenosis or regurgitation, or both, can be present. Re-
evaluation by physical examination, ECG, and echocardi-
ography is necessary for reassessment. In addition, exercise
stress testing or catheterization, or both, can be required for
patients whose physiologic and anatomic severity cannot
otherwise be determined.
Recommendations:
1. Athletes with residual mild, moderate, or severe
stenosis should follow the same recommendations as
previously defined for untreated patients.
2. Athletes with moderate to severe aortic regurgitation
should follow the recommendations in Task Force 3:
Valvular Heart Disease.
3. Because of the propensity for recurrence of LV
outflow obstruction in discrete subaortic stenosis
postoperatively, these patients require continued
follow-up and re-evaluation annually for exercise
recommendations. This recommendation also ap-
plies to all other forms of fixed AS.
Coarctation of the aorta— untreated. This abnormality is
characterized by obstruction usually present in the juxtaduc-
tal or juxtaligamental area. Severity is assessed by the arm
and leg pressure gradient, physical examination, exercise
testing, echocardiographic/Doppler studies, and cardiac
magnetic resonance (CMR) studies. Virtually all patients,
except those with mild coarctation, will undergo either
surgical repair or balloon dilation/stenting.
Recommendations:
1. Athletes with mild coarctation and the absence of
large collateral vessels or significant aortic root dila-
tion (z-score 3.0 or less) (score 3.0  3 standard
deviations from the mean for patient size), with a
normal exercise test and a small pressure gradient at
rest (usually 20 mm Hg or less between upper and
lower limbs), and a peak systolic blood pressure 230
mm Hg or less with exercise can engage in all
competitive sports.
2. Athletes with a systolic arm/leg gradient more than
20 mm Hg or exercise-induced hypertension with a
systolic blood pressure more than 230 mm Hg can
engage in only low-intensity competitive sports (class
IA) until treated.
Coarctation of the aorta—treated by surgery or balloon
angioplasty. The majority of patients will have coarctation
repair or balloon arterioplasty performed during childhood.
After repair, abnormalities can persist, such as a mild
residual gradient, ventricular hypertrophy, systemic hyper-
tension, and residual obstruction evident on exercise (9,10).
Before a decision for participation, minimal diagnostic
studies, including a chest radiograph, ECG, exercise testing,
and echocardiographic evaluation of LV function and aortic
anatomy, should be done. Magnetic resonance imaging can
be useful to document residual anatomical abnormalities,
aortic dilation, or aneurysm formation.
Recommendations:
1. Participation in sports, three or more months after
surgical or balloon angioplasty for coarctation of the
aorta, is permitted for athletes with a 20 mm Hg or
less arm/leg blood pressure gradient at rest and a
normal peak systolic blood pressure during rest and
exercise.
2. During the first postoperative year, athletes should
refrain from high-intensity static exercise (classes
IIIA, IIIB, and IIIC) and sports that pose the danger
of bodily collision.
3. After three months, if patients continue to be asymp-
tomatic, with normal blood pressure at rest and
exercise, all sports are permissible except those with a
large static component (particularly, classes IIIA,
IIIB, and IIIC).
4. For athletes with evidence of significant aortic dila-
tion, wall thinning, or aneurysm formation, partici-
pation should be restricted to low-intensity compet-
itive sports (classes IA and IB).
Elevated pulmonary resistance with congenital heart
disease. Patients who have pulmonary vascular disease and
congenital heart disease are at risk for sudden death during
sports activity. As pulmonary vascular obstruction progresses,
these patients develop cyanosis at rest and intense cyanosis with
exercise. Although most of these patients self-limit their
activity, they should not participate in competitive sports.
Patients who have suspected elevated pulmonary artery
pressure after operation or interventional catheterization for
shunt lesions should be evaluated by echocardiography
and/or cardiac catheterization before engaging in competi-
tive athletics.
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Recommendations:
1. If pulmonary artery peak systolic pressure is 30 mm
Hg or less, athletes can participate in all sports.
2. If pulmonary artery pressure is more than 30 mm Hg,
a full evaluation and individual exercise prescription
are required for athletic participation.
Ventricular dysfunction after cardiac surgery. Left
and/or right ventricular dysfunction can occur after
surgical treatment of both simple and complex congenital
heart diseases and affect exercise performance. Periodic
assessment of ventricular function is required for partic-
ipation in sports because ventricular function may dete-
riorate over time.
Recommendations:
1. For full participation, normal or near-normal ven-
tricular function is required (ejection fraction 50% or
more).
2. Athletes with mildly depressed ventricular function
(ejection fraction 40% to 50%) should participate in
low-intensity static competitive sports only (classes
IA, IB, and IC).
3. Athletes with moderately to severely depressed ven-
tricular function (ejection fraction less than 40%)
should not participate in competitive sports.
Cyanotic congenital cardiac disease— unoperated. Cya-
notic congenital heart disease is associated with exercise
intolerance and progressive hypoxemia with increasing ef-
fort. Patients are unlikely to engage in competitive sports
because of their own self-limiting activity. There are rare
patients with cyanotic congenital heart disease (such as
pulmonary stenosis or mildly elevated pulmonary vascular
resistance plus atrial or ventricular defects) who reach
adolescence or even adult life with mild cyanosis at rest and
shortness of breath only with exercise. These patients may
experience a profound increase in cyanosis during sports
participation.
Recommendation:
1. Patients with untreated cyanotic heart disease can
usually participate in low-intensity competitive
sports of only class IA.
Postoperative palliated cyanotic congenital heart disease.
Palliative surgical intervention can be performed to increase
pulmonary blood flow in patients with decreased flow or to
limit blood flow in those with excessive flow. Often these
patients have significant relief of symptoms at rest, but
arterial desaturation during exercise frequently persists.
Recommendation:
1. Patients can participate in low-intensity competitive
sports (class IA), provided that the following criteria
are met:
• Arterial saturation remains above approximately
80%
• Tachyarrhythmias associated with symptoms of
impaired consciousness not present
• There is not moderate/severe ventricular dys-
function.
Postoperative tetralogy of Fallot (T/F). The current treat-
ment for T/F is early repair, and patients have varying degrees
of pulmonary stenosis and mild/moderate pulmonary insuffi-
ciency. Diagnostic evaluation usually includes physical exami-
nation, chest radiograph, echocardiography, CMR, ambula-
tory ECG monitoring, and exercise testing. Cardiac
catheterization and/or exercise testing may be required for
complete evaluation in selected patients, particularly those with
significant cardiomegaly and/or symptoms. Patients with im-
portant residual abnormalities, such as a significant left-to-
right shunt, right ventricular hypertension, moderate-to-severe
pulmonary regurgitation, or right ventricular dysfunction, who
also have a history of syncope and/or arrhythmia, may be at risk
for sudden death (11).
Recommendations:
1. Athletes with an excellent repair should be allowed to
participate in all sports, providing that the following
criteria are met:
• Normal or near-normal right heart pressure
• No or only mild right ventricular volume overload
• No evidence of a significant residual shunt
• No atrial or ventricular tachyarrhythmia abnor-
mality on ambulatory ECG monitoring or exercise
testing
2. Patients with marked pulmonary regurgitation and
right ventricular volume overload, residual right ven-
tricular hypertension (peak systolic right ventricular
pressure greater than or equal to 50% systemic pres-
sure), or atrial or ventricular tachyarrhythmias,
should participate in low-intensity competitive sports
only (class IA).
Transposition of the great arteries (TGA)—post-
operative Mustard or Senning operation. Patients who
have had atrial repair of TGA can have significant hemo-
dynamic abnormalities including impaired systemic venous
return, abnormal right ventricular (systemic ventricular)
function, pulmonary stenosis or pulmonary hypertension,
abnormalities of pulmonary venous return, tricuspid insuf-
ficiency, and significant atrial or ventricular arrhythmias
(12). After atrial repair, the right ventricle is subjected to
systemic pressure, and because of the intrinsic properties of
the right ventricle its reserve is believed to be less than that
of the left ventricle. The consequences of hypertrophy and
dilation in a trained athlete after an otherwise excellent atrial
repair of transposition are unknown. Evaluation before
training and competition in moderate- and low-intensity
sports should include history and examination, chest radio-
graph, ECG, echocardiogram, CMR, ambulatory ECG
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monitoring, and exercise testing. For patients in whom data
are unclear with regard to hemodynamic abnormalities or
ventricular function, cardiac catheterization may be
necessary.
Recommendations:
1. Selected patients can engage in low and moderate
static/low dynamic competitive sports (classes IA and
IIA) provided there is:
• Mild or no cardiac chamber enlargement on chest
radiograph, echocardiography, or CMR
• No history of atrial flutter, supraventricular tachy-
cardia, or ventricular tachyarrhythmia
• No history of syncope or other cardiac symptoms
• A normal exercise test defined as normal duration,
workload, heart rate, ECG, and blood pressure
response for age and gender.
2. Patients not in this category require an individual-
ized exercise prescription.
Postoperative arterial switch for TGA. A significant co-
hort of patients have had arterial switch repair of TGA and
are now old enough to engage in competitive sports. These
patients have a low prevalence of ventricular dysfunction,
arrhythmia with symptoms, and hemodynamic sequelae
(with the possible exception of pulmonary artery or anasto-
motic stenosis and neoaortic root dilation). Only limited
exercise data are available.
Recommendations:
1. Athletes with normal ventricular function, normal
exercise test, and no atrial or ventricular tachyar-
rhythmias can participate in all sports.
2. Athletes with more than mild hemodynamic abnor-
malities or ventricular dysfunction can participate in
low and moderate static/low dynamic competitive
sports (classes IA, IB, IC, and IIA), provided that
their exercise test is normal.
Congenitally corrected transposition of the great arteries
(CCTGA). Usually, CCTGA is associated with other
congenital malformations of the heart, such as ventricular
septal defect, pulmonary stenosis, and systemic AV valve
abnormalities, which may dictate the level of participation
in competitive sports. These patients are at risk for devel-
opment of supraventricular tachycardia and spontaneous
AV block.
Recommendations:
1. Asymptomatic patients with CCTGA without other
cardiac abnormalities may be eligible for participa-
tion in class IA and IIA sports if there is no systemic
ventricle enlargement, no evidence of atrial or ven-
tricular tachyarrhythmia on ambulatory ECG moni-
toring or exercise testing or normal exercise tests
(including normal maximum oxygen consumption for
age and gender).
2. Periodic re-evaluation is important to detect devel-
opment of arrhythmias and deterioration of systemic
(right) ventricular function and systemic (tricuspid)
AV valve regurgitation. In particular, sports with a
large static component (classes IIIA, IIIB, IIIC)
such as power weightlifting are not recommended.
Postoperative Fontan operation. The Fontan operation is
characterized by systemic venous return bypassing the right
ventricle. The operation is used for the long-term palliation
of patients with tricuspid atresia or other complex types of
single ventricle. Although many patients improve clinically
after the Fontan operation, they usually have limited exer-
cise capacity and reduced cardiac output at rest and during
exercise (13). Postoperative arrhythmias have been associ-
ated with significant morbidity and mortality. Diagnostic
evaluation before sports participation should include a chest
radiograph, ECG, echocardiography or CMR, and exercise
testing with oxygen saturations.
Recommendations:
1. Athletes can participate in low-intensity competitive
sports (class IA).
2. Athletes can engage in class IB sports if they have
normal ventricular function and oxygen saturation.
Ebstein’s anomaly. A great deal of variability exists in the
severity of this malformation, which is characterized by
variable degrees of tricuspid regurgitation and right-heart
enlargement caused by a malformed and displaced tricuspid
valve. Cyanosis may be present due to atrial right-to-left
shunting. Even mild cases may be associated with important
arrhythmias. Severe cases can be associated with physical
disability and increased risk for sudden death with exercise.
Recommendations:
1. Athletes with a mild expression of Ebstein’s anomaly
without cyanosis, with normal right ventricular size,
and with no evidence of atrial or ventricular tachyar-
rhythmias can participate in all sports.
2. Athletes with tricuspid regurgitation of moderate
severity can participate in low-intensity competitive
sports (class IA) if there is no evidence of arrhythmia
on ambulatory ECG Holter monitoring other than
isolated premature contractions.
3. Athletes with severe Ebstein’s anomaly are precluded
from all sports participation. However, after surgical
repair, low-intensity competitive sports (class IA) can
be permitted if tricuspid regurgitation is absent or
mild, cardiac chamber size on chest radiograph or by
echocardiography is not substantially increased, and
symptomatic atrial or ventricular tachyarrhythmias
are not present on ambulatory ECG monitoring and
exercise test. Selected athletes with an excellent
hemodynamic result after repair may be permitted
additional participation on an individual basis.
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Congenital coronary artery anomalies. Congenital coro-
nary anomalies of wrong sinus origin are the second most
common cardiovascular cause of sudden death in young
athletes (1). The most common of these malformations is
anomalous origin of the left main coronary artery from the
anterior (right) sinus of Valsalva, with an acute angled bend
coursing between the pulmonary trunk and the anterior
aspect of the aorta (14,15). Rare cases of anomalous origin
of the right coronary artery from the left coronary sinus,
congenitally hypoplastic coronary arteries, and anomalous
origin of the left main coronary artery from the pulmonary
trunk have also been associated with sudden cardiac death
during exercise (1). Identification of these anomalies during
life can be difficult because patients often do not experience
warning symptoms, and rest and exercise ECGs are usually
normal. Coronary anomalies should be considered in ath-
letes with exertional syncope or symptomatic ventricular
arrhythmia and should be investigated using appropriate
studies such as echocardiography, CMR, or ultrafast com-
puted tomography imaging. Coronary arteriography is in-
dicated if other studies are not diagnostic. Surgery is usually
performed when the diagnosis is made (16).
Recommendations:
1. Detection of coronary anomalies of wrong sinus
origin in which a coronary artery passes between
great arteries should result in exclusion from all
participation in competitive sports.
2. Participation in all sports three months after success-
ful operation would be permitted for an athlete
without ischemia, ventricular or tachyarrhythmia, or
dysfunction during maximal exercise testing.
3. Athletes with previous myocardial infarction (MI)
should follow the appropriate recommendations in
Task Force 6: Coronary Artery Disease.
A discussion of coronary artery myocardial bridging appears
in Task Force 6: Coronary Artery Disease.
Kawasaki disease. Kawasaki disease, an acute, self-limited
vasculitis of unknown etiology, is now the most common
cause of acquired heart disease in children in the U.S. (17).
Coronary artery aneurysms develop in approximately 20% of
untreated children and in 4% of those treated with high-
dose intravenous gammaglobulin in the acute phase (18).
Coronary aneurysms, together with progressive coronary
artery stenosis, can lead to ischemic heart disease, MI, or
sudden death (19). Because coronary artery morphology
evolves over time, the risk of exercise for the individual
patient may change. Patients without coronary artery
changes on echocardiography at any stage of the illness
appear to have risk for ventricular tachyarrhythmias and
sudden death similar to that of the normal population in the
first 20 years after illness onset (19). When aneurysms
regress to normal lumen diameter, structural and functional
coronary abnormalities persist (20). Arteries with persistent
aneurysmal morphology may develop stenoses or occlusion,
increasing the risk of myocardial ischemia (21). The risk
associated with competitive sports in individuals who have
had Kawasaki disease depends upon the degree of coronary
artery involvement. Of note, because of the general cardio-
vascular benefits of exercise, all patients with Kawasaki
disease should avoid a sedentary lifestyle.
Recommendations:
1. Patients with no coronary artery abnormalities or
transient coronary artery ectasia resolving during the
convalescent phase of the disease are encouraged to
participate in all sports after six to eight weeks.
2. Patients with regressed aneurysms can participate in
all competitive sports if they have no evidence of
exercise-induced ischemia by stress testing with myo-
cardial perfusion imaging.
3. Patients with isolated small- to medium-sized aneu-
rysms in one or more coronary arteries and judged to
be at low risk for ischemic complications (normal left
ventricular function, absence of exercise-induced
ischemia or arrhythmia) may participate in low to
moderate static and dynamic competitive sports
(classes IA, IB, IIA, and IIB). Stress testing with
evaluation of myocardial perfusion should be re-
peated at one- to two-year intervals to monitor
ischemia and guide further recommendations about
sports competition.
4. Patients with one or more large coronary aneurysms
or multiple (segmented) or complex aneurysms with
or without obstruction to coronary flow may partici-
pate in class IA and IIA sports if they have no
evidence of reversible ischemia on stress testing,
normal LV function, and absence of exercise-induced
arrhythmia. Stress testing with evaluation of myocar-
dial perfusion should be repeated at one-year inter-
vals to monitor ischemia and guide further recom-
mendations about sports competition.
5. Athletes with recent MI or revascularization should
avoid competitive sports until their recovery is com-
plete— usually six to eight weeks. Those with normal
LV ejection fraction, exercise tolerance, absence of
reversible ischemia or myocardial perfusion testing,
and absence of exercise-induced arrhythmias can
participate in class IA and IB sports. Those with left
ventricular ejection fraction less than 40%, exercise
intolerance, or exercise-induced ventricular tachyar-
rhythmias should not participate in competitive
sports.
6. Patients with coronary lesions who are taking anti-
coagulants and/or antiplatelet drugs (aspirin, clopi-
dogrel) should not participate in sports that pose a
danger of high speed collision.
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